ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
Want to see AVBP full AI Analyst Report?
AVBP Stock Chart & Stats
$29.41
$0.14(0.52%)
At close: 4:00 PM EST
$29.41
$0.14(0.52%)
Day’s Range― - ―
52-Week Range$16.10 - $29.71
Previous CloseN/A
Volume49.09K
Average Volume (3M)556.73K
Market Cap
$1.30B
Enterprise Value$1.26B
Total Cash (Recent Filing)$312.82M
Total Debt (Recent Filing)$14.00K
Price to Earnings (P/E)―
Beta1.06
Next Earnings
May 13, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding44,201,622
10 Day Avg. Volume474,352
30 Day Avg. Volume556,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.35
Forecast
1Y Price Target
$43.22Price Target Upside46.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Oral, Brain‑penetrant Monotherapy AdvantageThe oral, chemotherapy‑free formulation with brain penetration could differentiate the drug by offering simpler administration and better central nervous system activity for patients with brain metastases compared with intravenous combination therapies.
Pipeline And ADC OptionalityEarly antibody‑drug conjugate programs, including a CDH17‑directed candidate, provide additional development pathways that could create upside beyond the lead program if early clinical activity is confirmed.
Pivotal Trial OutcomeA positive pivotal Phase 3 FURVENT readout showing superior efficacy versus chemotherapy in first-line EGFR exon 20 insertion lung cancer could materially increase the stock by validating the lead drug's clinical advantage.
Bears Say
Competitive Pressure From Existing TherapiesA competing therapy that can be used with or without chemotherapy in many patients may limit market uptake and pricing power for the drug even if clinical efficacy is demonstrated.
Financing And Dilution RiskLimited cash resources may require the company to seek additional financing before potential approvals, which could result in shareholder dilution and add execution risk to the development plan.
Readout Delay And Outcome UncertaintyA postponed pivotal trial readout raises uncertainty because improved performance in the control arm or other trial dynamics could increase the risk of an unfavorable outcome and amplify share volatility.
ArriVent BioPharma, Inc. News
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $16.10 and its highest was $29.71 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $1.30B.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is May 13, 2026 which is in 25 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Mar 05, 2026. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.846 by $0.006.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.9.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 44,201,622 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.846. Following the earnings report the stock price went down -7.208%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ArriVent BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.22 (46.96% Upside)
$43.22 (46.96% Upside)
Blogger Sentiment
Bullish
AVBP Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 151.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.86%
12-Months-Change
Fundamentals
Return on Equity
-62.48%
Trailing 12-Months
Asset Growth
21.18%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$43.22
▲(46.96% Upside)
Technical Analysis
uniQure
―
Iovance Biotherapeutics
―
Relay Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Ownership Overview
Currently, No data available
---